MannKind faces revenue and margin pressure amid competition and reliance on niche products.

MannKind Corporation remains a Hold as its revenue growth depends heavily on niche products like Furoscix, while facing margin pressures. The launch of Tresmi by United Therapeutics threatens MannKind's royalties from Tyvaso DPI, increasing competitive risks and underscoring MannKind's junior partner role. Although pipeline products like MNKD-201 and ralinepag DPI offer potential, they face significant clinical and commercial challenges. Elevated SG&A and R&D expenses indicate a strategic shift, but MannKind must demonstrate its ability to succeed independently from United Therapeutics.